<SEC-DOCUMENT>0001193125-25-189133.txt : 20250827
<SEC-HEADER>0001193125-25-189133.hdr.sgml : 20250827
<ACCEPTANCE-DATETIME>20250827073853
ACCESSION NUMBER:		0001193125-25-189133
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250827
DATE AS OF CHANGE:		20250827

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285969
		FILM NUMBER:		251259752

	BUSINESS ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		100 CAMBRIDGEPARK DRIVE
		STREET 2:		SUITE 101
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02140
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d904071d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-285969 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus Dated
March&nbsp;31, 2025) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g904071g51v03.jpg" ALT="LOGO" STYLE="width:1.65903in;height:0.565972in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to $119,699,305</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a Sales
Agreement, or the sale agreement, with Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, or Stifel, dated December&nbsp;23, 2022, relating to the sale of shares of our common stock, $0.0001 par value per share. We previously filed a Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-263541)</FONT> on March&nbsp;14, 2022 and a prospectus supplement on December&nbsp;23, 2022, or the prior prospectus, covering the
offering, issuance and sale by us of up to a maximum aggregate offering price of $125.0&nbsp;million of our common stock that may be issued and sold from time to time under the sale agreement. As of the date of this prospectus supplement, we have
sold 1,275,758 shares of our common stock for gross proceeds of approximately $5,300,695 in accordance with the sale agreement under the prior prospectus. In accordance with the terms of the sale agreement, pursuant to this prospectus supplement we
may offer and sell shares of our common stock from time to time through Stifel, acting as our sales agent, having an aggregate offering price of up to $119,699,305, which amount is in addition to the shares of common stock that we have sold to date
in accordance with the sale agreement under the prior prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol
&#8220;VOR.&#8221; On August&nbsp;25, 2025, the last reported sale price of our common stock was $2.06 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any,
under this prospectus supplement will be made by any method permitted that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Stifel
is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Stifel and us.
There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel will be entitled to compensation under the terms of
the sale agreement at a fixed commission rate up to 3.0% of the gross sales price per share sold under the sale agreement. In connection with the sale of common stock on our behalf, Stifel will be deemed to be an &#8220;underwriter&#8221; within the
meaning of the Securities Act and the compensation of Stifel will be deemed to be underwriting commissions or discounts. See the section titled &#8220;Plan of Distribution&#8221; beginning on
<FONT STYLE="white-space:nowrap">page&nbsp;S-13&nbsp;of</FONT> this prospectus supplement regarding the compensation to be paid to Stifel. We have also agreed to provide indemnification and contribution to Stifel against certain liabilities,
including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#8220;<A HREF="#supptoc904071_4">Risk Factors</A>&#8221; beginning on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement and under similar headings in the other documents that are
incorporated by reference into this prospectus supplement and the accompanying base prospectus concerning factors you should consider before investing in our common stock. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the
adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is August&nbsp;27, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc904071_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This sale agreement prospectus supplement is a part of a registration statement that we have filed on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;with</FONT> the U.S. Securities and Exchange Commission, or the SEC, utilizing a &#8220;shelf&#8221; registration process. By using a shelf registration statement, we may offer any combination of
our securities described in our base prospectus included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $350.0&nbsp;million. We may offer, issue and sell shares of our common stock having an
aggregate offering price of up to $119,699,305&nbsp;from time to time under this prospectus supplement and on terms to be determined by market conditions at the time of the offering. The $119,699,305&nbsp;of common stock that may be offered, issued
and sold under this prospectus supplement is included in the $350.0&nbsp;million of securities that may be offered, issued and sold by us pursuant to our shelf registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement and the accompanying base prospectus,
together with the information incorporated by reference as described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement or
incorporated by reference into the accompanying base prospectus, and any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering. These documents contain important information that you should
consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement describes the terms of this offering of common stock and also adds to and
updates information contained in the accompanying base prospectus and the documents incorporated by reference into this prospectus supplement and the base prospectus. To the extent there is a conflict between the information contained in this
prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectus supplement or the base prospectus that was filed with the SEC before the date of this prospectus supplement, on the
other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference
into this prospectus supplement&#8212;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor
Stifel have authorized anyone to provide you with information that is different from that contained in this prospectus supplement and the accompanying base prospectus or in any free writing prospectus we may authorize to be delivered or made
available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not, and Stifel is not, making an offer to sell these securities in any jurisdiction where
the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement and the accompanying base prospectus, the documents incorporated by reference in this prospectus supplement and the base prospectus,
and in any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and
prospects may have changed since those dates. You should read this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference in this prospectus supplement and the base prospectus, and any free writing
prospectus or prospectus supplement that we have authorized for use in connection with this offering, in their entirety before making an investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus supplement, the terms the &#8220;Company,&#8221; &#8220;Vor,&#8221; &#8220;Vor
Biopharma,&#8221; &#8220;Vor Bio,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Vor Biopharma Inc., a Delaware corporation, and its consolidated subsidiary. &#8220;VOR
BIOPHARMA&#8221; and the Vor logo and other trademarks, trade names or service marks of Vor Biopharma Inc. appearing in this prospectus supplement are the property of Vor Biopharma Inc. All other trademarks, trade names and service marks appearing
in this prospectus supplement or incorporated by reference into this prospectus supplement and the accompanying base prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this
prospectus supplement or the accompanying base prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of
our company and this offering, we encourage you to read and consider carefully this entire prospectus supplement, including the information incorporated by reference into this prospectus supplement and the accompanying base prospectus, and the
information included in any free writing prospectus or prospectus supplement that we have authorized for use in connection with this offering, including the information referred to under the heading &#8220;Risk Factors&#8221; in this prospectus
supplement and the accompanying base prospectus, our annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2024, our quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the quarters ended March&nbsp;31, 2025 and June&nbsp;30, 2025, and our financial statements and the related notes and other documents incorporated by reference into this prospectus supplement and the base prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on developing a novel therapy for the treatment of autoimmune diseases. In June 2025, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> telitacicept from RemeGen Co., Ltd., or RemeGen. Telitacicept is approved
in China for the treatment of systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis, or gMG. A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia
including Japan to support potential approval in the United States, Europe, and Japan. Telitacicept is a novel fusion protein for treating autoimmune diseases. It is constructed with the extracellular domain of the human transmembrane activator and
calcium modulator and cyclophilin ligand interactor receptor and the fragment crystallizable domain of human immunoglobulin G. Telitacicept targets and acts on two cell signaling molecules critical for B lymphocyte development: B cell lymphocyte
stimulator, also known as B cell activating factor, or BAFF, and a proliferation inducing ligand, or APRIL, which allows it to effectively reduce B cell mediated autoimmune responses that are implicated in several autoimmune diseases. Pursuant to
our license agreement with RemeGen, we were granted an exclusive license to develop and commercialize telitacicept outside of the Greater China region, which includes mainland China, Hong Kong, Macau and Taiwan. RemeGen retains development and
commercialization rights in Greater China. Our broader development plan includes exploring development of telitacicept in additional autoantibody-driven diseases where BAFF / APRIL signaling is a validated target, supported by prior clinical
experience and mechanistic rationale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information concerning the Company is contained in the documents that we file with the SEC as a reporting company under the Exchange Act, which are accessible
at www.sec.gov. We were incorporated under the laws of the State of Delaware in December 2015. Our mailing address is currently P.O. Box 380121, Cambridge, Massachusetts 02238. Effective as of September&nbsp;1, 2025, our mailing address and
principal executive offices will be located at 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116. Our telephone number <FONT STYLE="white-space:nowrap">is&nbsp;(617)&nbsp;655-6580.&nbsp;Our&nbsp;internet</FONT> website address is
www.vorbio.com. The information contained on our website is not incorporated by reference into this prospectus supplement, and you should not consider any information contained on, or that can be accessed through, our website as part of this
prospectus supplement or in deciding whether to purchase our securities. The inclusion of our website address in this prospectus supplement is only an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VOR BIOPHARMA, our Vor logo, and our other trademarks or service marks appearing in this prospectus supplement are our property. This prospectus supplement
and the information incorporated herein by reference </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, the trademarks and trade names in this
prospectus supplement may be referred to without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbols, but such references should not be construed
as any indicator that their respective owners will not assert their rights thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller
Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act. For so long as we remain an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including only being required to present two years of audited
financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these
provisions until we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&nbsp;December&nbsp;31, 2026, (ii) the last day of the fiscal year in which we have
more than $1.235&nbsp;billion in total annual gross revenues, (iii)&nbsp;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the
prior three-year period. We may choose to take advantage of some but not all of these reduced reporting requirements. We have taken advantage of certain reduced reporting requirements in this prospectus supplement. Accordingly, the information
contained herein may be different than you might obtain from other public companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised
accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised
accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in
this prospectus supplement may be different than the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result
of these elections, which may result in a less active trading market for our common stock and higher volatility in our share price. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held <FONT
STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if
either (i)&nbsp;the market value of our shares held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed
fiscal year and the market value of our shares held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we
may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited
financial statements in our Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;and,</FONT> similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive
compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common stock offered by us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shares of our common stock having an aggregate offering price of up to $119,699,305.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding immediately after this offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Up to 183,752,410&nbsp;shares,
assuming sales of 58,106,458&nbsp;shares of our common stock in this offering at an offering price of $2.06 per share, which was the last reported sale price per share of our common stock on the Nasdaq Global Select Market on August&nbsp;25, 2025.
The actual number of shares of common stock issued will vary depending on the sales price under this offering.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Plan of Distribution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#8220;At the market offering&#8221; that may be made from time to time on the Nasdaq Global Select Market or other existing trading market for our common stock through our agent, Stifel. See the section entitled &#8220;Plan of
Distribution&#8221; on page <FONT STYLE="white-space:nowrap">S-13</FONT> of this prospectus supplement.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Use of Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We intend to use the net proceeds of this offering, if any, for working capital, capital expenditures and other general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or
technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. See the section entitled &#8220;Use of
Proceeds&#8221; on page&nbsp;S-10 of this prospectus supplement.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Risk Factors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">See &#8220;<A HREF="#supptoc904071_4">Risk Factors</A>&#8221; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-6</FONT> of this prospectus supplement and under similar headings in other documents incorporated by
reference into this prospectus supplement and the accompanying base prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VOR</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 125,645,952 shares
of our common stock outstanding as of June&nbsp;30, 2025 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">94,640,388 shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30,
2025, at a weighted-average exercise price of $1.28 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,761,538 shares of common stock issuable upon the exercise of outstanding stock options issued subsequent to
June&nbsp;30, 2025, at a weighted-average exercise price of $2.19 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,909,136 shares of common stock issuable upon vesting and settlement of outstanding restricted stock units as of
June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,831,651 shares of common stock issuable upon vesting and settlement of outstanding restricted stock units
issued subsequent to June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,027,849 shares of common stock reserved for future issuance under our Amended and Restated 2021 Equity
Incentive Plan, or the 2021 Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,318,649 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, or the
ESPP, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">69,668,889 shares of common stock reserved for future issuance under our 2023 Inducement Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,089,839,075 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average exercise price of the outstanding stock options described above does not give effect to the
previously announced stock option repricing approved by our board of directors on February&nbsp;3, 2025. Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding stock options or warrants
described above. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and
uncertainties described below together with all other information contained in this prospectus supplement, the accompanying base prospectus and in our filings with the SEC that we have incorporated by reference in this prospectus supplement and the
accompanying base prospectus. If any of the following risks actually occurs, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might
lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section below titled &#8220;Special
Note Regarding Forward-Looking Statements.&#8221; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management will have broad discretion as to the use of the proceeds from this offering, and may not use the proceeds effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, if any, including for any of the purposes described in the
section entitled &#8220;Use of Proceeds&#8221; on page <FONT STYLE="white-space:nowrap">S-10</FONT> of this prospectus supplement, and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being
used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our
net proceeds in ways that ultimately increase the value of your investment. We intend to use the net proceeds of this offering for working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to
invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. The failure by
our management to apply these funds effectively could harm our business. Pending their use, we plan to invest the net proceeds from this offering in a variety of capital preservation investments, which may consist of money market funds and
marketable debt securities, including short-term, investment-grade corporate bonds and U.S. Treasury securities. These investments may not yield a favorable return to our shareholders. If we do not invest or apply the net proceeds from this offering
in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our share price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you
purchase shares of our common stock sold in this offering, you may experience immediate and substantial dilution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming that 58,106,458 shares
of our common stock are sold at a price of $2.06 per share, the last reported sale price of our common stock on The Nasdaq Global Select Market on August&nbsp;25, 2025, for aggregate gross proceeds of approximately $119.7&nbsp;million, and after
deducting estimated commissions and offering expenses payable by us, you would experience immediate dilution of $9.62 per share, representing the difference between our as adjusted net tangible book value per share as of June&nbsp;30, 2025 after
giving effect to this offering and the assumed sale price. The exercise of outstanding stock options or warrants or the vesting and settlement of restricted stock units may result in further dilution of your investment. See the section titled
&#8220;Dilution&#8221; below for a more detailed illustration of the dilution you may incur if you participate in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience
future dilution as a result of future equity offerings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we expect to in the future offer additional shares
of common stock or other securities convertible into or exchangeable for our shares of common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater
than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could have rights superior to existing stockholders. The price per share at which we sell additional shares of common stock or other securities convertible into or exchangeable for our shares of
common stock in future transactions may be higher or lower than the price per share in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The shares of common stock will be sold in
&#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors who purchase
shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and numbers of shares
sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares we will issue under the sale agreement, at any one time or in total, is uncertain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sale agreement and compliance with applicable law, we have the discretion to deliver placement notices to Stifel at any
time throughout the term of the sale agreement. The number of shares that are sold by Stifel after delivering a placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set in the placement
notice. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued or the
resulting gross proceeds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital
appreciation, if any, will be your sole source of gains and you may never receive a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely on an
investment in our common stock to provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a
result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements contained or incorporated by reference in this prospectus supplement, the accompanying base prospectus and any related free writing
prospectus constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&nbsp;27A of the Securities Act and
Section&nbsp;21E of the Exchange Act. In some cases, you can identify forward-looking statements by the words &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; or &#8220;would,&#8221; and/or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements involve known and unknown risks, uncertainties and other
factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such
forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement, we caution you that these statements are based on a combination of facts and factors
currently known by us and our expectations of the future, about which we cannot be certain. These forward-looking statements include, without limitation, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our clinical trials of our product candidate and preclinical and clinical
trials for any future products candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become
available and plans with respect to our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for, our product candidate and any future product candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the diseases treated by our product candidate and any future product
candidates, and to enroll patients in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the market acceptance and opportunity for and clinical utility of our product
candidate and any future product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for any product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidate or any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue and capital requirements and our need for or
ability to obtain additional funding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel, including executive officers and members of
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our product candidate or any future
product candidates, and the scope of such protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash, cash equivalents and marketable securities will be
sufficient to fund our future operating expenses and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competition or our industry;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated proceeds from this offering, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In evaluating such forward-looking statements, you should specifically consider various factors, including the risks outlined under the heading &#8220;Risk
Factors&#8221; contained in this prospectus supplement, the accompanying base prospectus and any related free writing prospectus, our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> in our subsequently
filed Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;and</FONT> Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> if applicable, as well as our other filings with the SEC. The discussion of risks
and uncertainties set forth in those filings is not necessarily a complete or exhaustive list of all risks facing us at any particular point in time. As a result of these factors, we cannot assure you that the forward-looking statements in this
prospectus supplement will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law. Forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. You should carefully read
this prospectus supplement, the accompanying base prospectus and any related free writing prospectus, together with the information incorporated herein or therein by reference, and with the understanding that our actual future results may materially
differ from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $119,699,305 from time to time. Because there is no minimum offering
amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize
the sale agreement with Stifel as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from the sale of the securities offered hereby for
working capital, capital expenditures and other general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current
plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. We have not determined the exact amounts we plan to spend on any of the items listed above or the timing of these expenditures. The
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the actual net proceeds from this offering (which will depend on the market price of our common stock during the sales period, any limits
we may set with Stifel in any applicable placement notice and the demand for our common stock), the progress of our development and commercialization efforts, the status of and results from clinical trials, as well as any collaborations that we may
enter into with third parties for our product candidates, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, which may
consist of money market funds and marketable debt securities, including short-term, investment-grade corporate bonds and U.S. Treasury securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of June&nbsp;30, 2025 was approximately $(1,506)&nbsp;million, or $(11.98) per share. Net tangible book value per share is
determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of June&nbsp;30, 2025. Dilution with respect to net tangible book value per share represents the difference between
the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the assumed sale of 58,106,458 shares of our common stock in this offering at an assumed public offering price of $2.06 per share, the
last reported sale price of our common stock on The Nasdaq Global Select Market on August&nbsp;25, 2025, and after deducting estimated commissions and offering expenses payable by us, our as adjusted net tangible book value as of June&nbsp;30, 2025
would have been approximately $(1,390)&nbsp;million, or $(7.56) per share. This represents an immediate increase in net tangible book value of $4.42 per share to existing stockholders and immediate dilution of $9.62 per share to investors purchasing
our common stock in this offering at the assumed public offering price. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11.98)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of June&nbsp;30, 2025, after giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.56)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors purchasing our common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 58,106,458 additional shares of our common stock are
sold during the term of the sale agreement at a price of $2.06 per share, the last reported sale price of our common stock on The Nasdaq Global Select Market on August&nbsp;25, 2025, for aggregate gross proceeds of approximately $119.7&nbsp;million.
The shares subject to the sale agreement may be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed public offering price of $2.06 per share shown in the table above,
assuming all of our common stock in the aggregate amount of approximately $119.7&nbsp;million during the term of the sale agreement is sold at that price, would decrease our as adjusted net tangible book value per share after the offering to $(8.44)
per share and would increase the dilution in net tangible book value per share to new investors in this offering to $11.50 per share, after deducting estimated commissions and offering expenses payable by us. A decrease of $1.00 per share in the
price at which the shares are sold from the assumed public offering price of $2.06 per share shown in the table above, assuming all of our common stock in the aggregate amount of approximately $119.7&nbsp;million during the term of the sale
agreement is sold at that price, would increase our as adjusted net tangible book value per share after the offering to $(5.83) per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $6.89
per share, after deducting estimated commissions and offering expenses payable by us. This information is supplied for illustrative purposes only and may differ based on the actual public offering price and the actual number of shares offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 125,645,952 shares of our common stock outstanding as of
June&nbsp;30, 2025 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">94,640,388 shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30,
2025, at a weighted-average exercise price of $1.28 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,761,538 shares of common stock issuable upon the exercise of outstanding stock options issued subsequent to
June&nbsp;30, 2025, at a weighted-average exercise price of $2.19 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,909,136 shares of common stock issuable upon vesting and settlement of outstanding restricted stock units as of
June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,831,651 shares of common stock issuable upon vesting and settlement of outstanding restricted stock units
issued subsequent to June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,027,849 shares of common stock reserved for future issuance under our Amended and Restated 2021 Equity
Incentive Plan, or the 2021 Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,318,649 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, or the
ESPP, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">69,668,889 shares of common stock reserved for future issuance under our 2023 Inducement Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,089,839,075 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average exercise price of the outstanding stock options described above does not give effect to the previously announced
stock option repricing approved by our board of directors on February&nbsp;3, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that options, restricted stock units and warrants
outstanding as described above have been or may be exercised or settle, as applicable, or other shares issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt
securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We previously entered into a sale agreement with Stifel relating to the sale of shares of our common stock from time to time through Stifel acting as agent.
As of the date of filing of this prospectus supplement, we may offer and sell shares of our common stock having an aggregate offering price of up to $119,699,305 under the sale agreement, which amount is in addition to the shares of common stock we
have sold to date in accordance with the sale agreement under the prior prospectus. Sales of our shares of common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that is deemed to be an
&#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we wish to issue and sell our shares of common
stock under the sale agreement, we will notify Stifel of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which
sales may not be made. Once we have so instructed Stifel, unless Stifel declines to accept the terms of such notice, Stifel has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such
shares up to the amount specified on such terms. The obligations of Stifel under the sale agreement to sell our shares of common stock are subject to a number of conditions that we must meet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The settlement of sales of shares between us and Stifel is generally anticipated to occur on the second trading day following the date on which the sale was
made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Stifel may agree upon. There is no arrangement for funds
to be received in an escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Stifel a commission up to 3.0% of the aggregate gross proceeds we receive from
each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.
In addition, we have agreed to reimburse Stifel for the fees and disbursements of its counsel, in connection with the filing of this prospectus supplement, in an amount not to exceed $75,000, in addition to certain ongoing disbursements of its legal
counsel, payable in an amount of up to $15,000 in connection with each triggering event date on which the Company is required to provide a certificate, unless we and Stifel otherwise agree. We estimate that the total expenses for the offering,
excluding any commissions or expense reimbursement payable to Stifel under the terms of the sale agreement, will be approximately $125,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the
sale of such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel will provide written confirmation to us before the open on the Nasdaq Global Select Market on the day following each day on
which our shares of common stock are sold under the sale agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of our shares of common stock on our behalf, Stifel will be deemed to be an &#8220;underwriter&#8221; within the meaning of the
Securities Act, and the compensation of Stifel will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Stifel against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to
contribute to payments Stifel may be required to make in respect of such liabilities. We and Stifel may each terminate the sale agreement at any time upon ten days&#8217; prior notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of our shares of common stock pursuant to the sale agreement will terminate upon the earlier of (i)&nbsp;the sale of all shares of common stock
subject to the sale agreement and (ii)&nbsp;the termination of the sale agreement as permitted therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary of the material provisions of the sale agreement does not purport to be a complete statement of
its terms and conditions. A copy of the sale agreement is filed as an exhibit to the registration statement of which this prospectus supplement forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and
our affiliates, for which services they may in the future receive customary fees. In the course of its business, Stifel may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Stifel may at any time
hold long or short positions in such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a
website maintained by Stifel, and Stifel may distribute the prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the common stock offered by this prospectus supplement will be passed upon by Cooley LLP, New York, New York. Latham&nbsp;&amp; Watkins LLP is
counsel for Stifel, Nicolaus&nbsp;&amp; Company, Incorporated in connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, GC&amp;H
Investments, LLC and GC&amp;H Investments, a California partnership, which are entities beneficially owned by current and former partners and associates of Cooley LLP, beneficially hold an aggregate of 35,350 shares of our common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report <FONT
STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;for&nbsp;the</FONT> year ended December&nbsp;31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the
Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial
statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;we</FONT> filed with the SEC under the
Securities Act. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering
under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor Stifel have authorized anyone to provide you with information that is different
from that contained in this prospectus supplement, the accompanying base prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of
any date other than the date on the front page of this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the common stock offered by this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy
statements and other information regarding issuers that file electronically with the SEC, including Vor. The address of the SEC website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.vorbio.com. Information contained in or accessible through our website does not constitute a part of this prospectus supplement
and is not incorporated by reference in this prospectus supplement. We have included our website address as an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc904071_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus supplement, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus supplement <FONT STYLE="white-space:nowrap">is&nbsp;001-39979.&nbsp;The</FONT>
documents incorporated by reference into this prospectus supplement contain important information about us that you should read. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents
are incorporated by reference into this prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;20, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2025 and June&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025071349/vor-20250331.htm">May<U></U>&nbsp;
14, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025107276/vor-20250630.htm">August<U></U>&nbsp;12, 2025</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525003259/d861124d8k.htm">January
<U></U>&nbsp;8, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525021763/d921842d8k.htm">February<U></U>&nbsp;
6, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525072340/d932261d8k.htm">April<U></U>&nbsp;
3, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525096692/d898205d8k.htm">April<U></U>&nbsp;
25, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525115554/d924194d8k.htm">May<U></U>&nbsp;
8, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525123141/d927316d8k.htm">May<U></U>&nbsp;
20, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525125833/d95113d8k.htm">May<U></U>&nbsp;
23, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525147339/d27026d8k.htm">June<U></U>&nbsp;
26, 2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525157638/d933755d8k.htm">July<U></U>&nbsp;
10, 2025</A>; and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525162644/d24616d8k.htm">July<U></U>&nbsp;22, 2025</A> (to the extent the information in such reports is filed and not furnished);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Revised Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525107123/d74158ddefr14a.htm">Schedule
 14A</A> filed with the SEC on April&nbsp;30, 2025 (to the extent the information therein is filed and not furnished); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1817229/000114036125029749/ny20051455x2_def14a.htm">Schedule
 14A</A> filed with the SEC on August&nbsp;8, 2025 (to the extent the information therein is filed and not furnished); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock as described in <A HREF="http://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-ex4_3.htm">Exhibit
 4.3</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on March&nbsp;20, 2025, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus supplement all documents (other than current reports furnished under Item 2.02 or Item 7.01 of <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;and</FONT> exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the
initial filing of the registration statement of which this prospectus supplement forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus supplement but prior to the termination of the
offering. These documents include periodic reports, such as Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;Quarterly</FONT> Reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;and</FONT> Current Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K,&nbsp;as</FONT> well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to
whom a prospectus supplement is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement but not delivered with the prospectus supplement,
including exhibits which are specifically incorporated by reference into such documents. Requests before September&nbsp;1, 2025 should be directed to: Vor Biopharma Inc., Attn: Investor Relations, P.O. Box 380121, Cambridge, Massachusetts 02238, <FONT
STYLE="white-space:nowrap">(617)&nbsp;655-6580.</FONT> Requests on or after September&nbsp;1, 2025 should be directed to: Vor Biopharma Inc., Attn: Investor Relations, 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116, <FONT
STYLE="white-space:nowrap">(617)&nbsp;655-6580.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by
reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference
into this document modifies or supersedes the statement. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g904071g65s86.jpg" ALT="LOGO" STYLE="width:3.69449in;height:1.32085in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$350,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">From time to time, we may offer and sell up to $350,000,000 of any combination of the securities described in this prospectus in one or more
offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of
the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may
also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before
you invest in any of the securities being offered. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting
company&#8221; under the federal securities laws and, as such, are subject to reduced public company reporting requirements. See &#8220;Summary&#8212;Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#8221; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;VOR.&#8221; On March&nbsp;18, 2025, the last reported
sales price of our common stock was $0.8265&nbsp;per share.<B> </B>The applicable prospectus supplement will contain information, where applicable, as to any other listing on The Nasdaq Global Select Market or any securities market or other exchange
of the securities, if any, covered by the prospectus supplement. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We will sell these securities directly to investors, through agents
designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this
prospectus and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable
fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus
supplement. </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B></B><B><I>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described
under the heading &#8220;<A HREF="#tx904071_3">Risk Factors</A>&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference
into this prospectus.</I></B><B> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March&nbsp;31, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx904071_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;), utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration statement, we may sell any combination of the securities described in this prospectus in one or more offerings up to
a total aggregate offering price of $350,000,000. This prospectus provides you with a general description of the securities we may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the
terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we
may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus
supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information By Reference,&#8221; before investing in any of the
securities offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS
SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information that we have provided or incorporated by reference in this prospectus, any
applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those
contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not
contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not
constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus
constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even
though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated herein by reference contain summaries of certain provisions contained in some of the
documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed,
will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More
Information.&#8221; </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in
making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading
&#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also
carefully read the information incorporated by reference into this prospectus, including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is a part, before making your investment
decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus, the terms the &#8220;Company,&#8221; &#8220;Vor
Biopharma,&#8221; &#8220;Vor Bio,&#8221; &#8220;Vor,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Vor Biopharma Inc., a Delaware corporation, and its consolidated subsidiary,
and &#8220;our board of directors&#8221; refers to the board of directors of Vor Biopharma Inc. &#8220;VOR BIOPHARMA&#8221; and the Vor Biopharma logo and other trademarks, trade names or service marks of Vor Biopharma Inc. appearing in this
prospectus are the property of Vor Biopharma Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
company harnessing the power of cell and genome engineering to develop potentially transformative therapies in acute myeloid leukemia (&#8220;AML&#8221;), a devastating disease with few treatment options. AML is the most common type of acute
leukemia in adults and one of the deadliest and most aggressive blood cancers, affecting approximately 20,000 newly diagnosed patients each year in the United&nbsp;States. Leveraging our expertise in hematopoietic stem cell (&#8220;HSC&#8221;)
biology and genome engineering, we genetically modify HSCs to remove surface targets and then provide these cells as hematopoietic cell transplants to patients. Once these cells engraft into bone marrow, the patient&#8217;s healthy cells are
shielded because they no longer express the surface target, leaving only the cancerous cells exposed. We believe this will unlock the potential of targeted therapies to selectively destroy cancerous cells while shielding healthy cells. As a result,
our shielded transplants are designed to limit <FONT STYLE="white-space:nowrap">the&nbsp;on-target&nbsp;toxicities</FONT> associated with these targeted therapies, thereby enhancing their utility, and broadening their applicability. We intend to
pair our shielded transplants with targeted therapeutics such as antibody drug conjugates or VCAR33, a chimeric antigen receptor T cell therapy designed to target CD33, to bring potentially transformative outcomes to patients and establish a new
standard of care Treatment System in AML. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information concerning the Company is contained in the documents that we file with the SEC, as a reporting company under the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are accessible at www.sec.gov. Our website address is www.vorbio.com. The information contained on, or that can be accessed through, our website is not a part of this
prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mailing address is 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140. Our telephone number is <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-655-6580.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller
Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012
(&#8220;JOBS Act&#8221;). For so long as we remain an emerging growth company, we may take advantage of relief </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from certain reporting requirements and other obligations that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including only being required to present two years of audited
financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of
these provisions until we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&nbsp;December&nbsp;31, 2026, (ii) the last day of the fiscal year in which we
have more than $1.07&nbsp;billion in total annual gross revenues, (iii)&nbsp;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the
prior three-year period. We may choose to take advantage of some but not all of these reduced reporting requirements. We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein
may be different than you might obtain from other public companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised
accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised
accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in
this prospectus may be different than the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these
elections, which may result in a less active trading market for our common stock and higher volatility in our share price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a
&#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual
revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting
company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose
to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, up to a total aggregate offering price of $350,000,000 from time to time in
one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This
prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and
other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important United States federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the
time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to
consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors
or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in
the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those underwriters or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated net proceeds to us. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B>. We may issue shares of our common stock from time to time. The
holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares
of preferred stock, the holders of our common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common
stock are entitled to share ratably in all net assets remaining after payment of all of our debts and other liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Our common stock does not carry any preemptive
rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B>. We may issue shares of our preferred stock from time to time, in one or more series. Under our Amended and
Restated Certificate of Incorporation (the &#8220;Restated Certificate&#8221;), our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or the rules of any
stock exchange or market on which our securities are then traded), to designate up to 10,000,000 shares of preferred stock in one or more series and to determine the designations, voting powers, preferences and rights of each series of the preferred
stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares
constituting any series or the designation of any series, any or all of which may be greater than the rights of the common stock. Any convertible preferred stock we may issue will be convertible into our common stock or exchangeable for our other
securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. You should refer to our Restated Certificate and our Bylaws, both of which are included as exhibits to documents incorporated by
reference in the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under this
prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will
file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of
preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the
series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities</I></B>. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or
as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the
manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or preferred stock. Conversion may be mandatory or at the
holder&#8217;s option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under one or more documents called
indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable
prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. Forms of
indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants.</I></B> We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series.
We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the
warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration
statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement or will be incorporated by reference from reports that we file with the SEC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant
agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2024, which is on file with the SEC and is incorporated herein by reference, as updated by any subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus, before deciding whether
to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors described in the documents referenced above could adversely affect our business, operating results
and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we
currently believe are immaterial may also significantly impair our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related free
writing prospectus constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&nbsp;27A of the Securities Act of
1933, as amended (the &#8220;Securities Act&#8221;), and Section&nbsp;21E of the Exchange Act. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221;
&#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions intended to identify statements about the future. From time to time, we publish forward-looking statements relating to matters such as
anticipated financial performance, business prospects, technological developments, new products, research and development activities and other aspects of our present and future business operations as well as similar matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s actual
results, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. While it is
impossible to identify or predict all such matters, these differences may result from, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our preclinical studies and clinical trials of our product candidates,
including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our
research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success of our <FONT STYLE="white-space:nowrap">in-house</FONT> or third-party clinical
manufacturing capabilities and efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for, our product candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the diseases treated by our product candidates, and to enroll patients in
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the market acceptance and opportunity for and clinical utility of our product
candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for any product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements, our need for or ability to
obtain additional funding and our ability to continue as a going concern; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel, including executive officers and members of
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our product candidates, and the scope
of such protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash, cash equivalents and marketable securities will be
sufficient to fund our future operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating such forward-looking statements, you should specifically consider various factors, including the risks
outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus, any accompanying prospectus supplement and any related free writing prospectus, and in our most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and any Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we subsequently file with the SEC. The discussion of
risks and uncertainties set forth in those filings is not necessarily a complete or exhaustive list of all risks facing us at any particular point in time. As a result of these factors, we cannot assure you that the forward-looking statements in
this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard
these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as required by law. Forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based on information available to us as of the date of this prospectus. While we believe such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some
of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, the events
and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the section titled &#8220;Risk
Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus, any accompanying prospectus supplement and any related free writing prospectus, together with the
information incorporated herein or therein by reference, and with the understanding that our actual future results may materially differ from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any
applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for
working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans,
commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any
securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our Restated Certificate authorizes us to issue up to 400,000,000 shares of common stock, $0.0001 par value
per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. As of December&nbsp;31, 2024, 124,776,152 shares of common stock were outstanding and no shares of preferred stock were outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of our Restated Certificate as well as our Amended and
Restated Bylaws (&#8220;Bylaws&#8221;), and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). This information is qualified entirely by reference to the applicable provisions of our Restated Certificate,
Bylaws and the DGCL. For information on how to obtain copies of our Restated Certificate and Bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#8220;Where You Can Find Additional Information.&#8221;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the
election of directors. The affirmative vote of holders of at least 662/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our Restated Certificate,
including provisions relating to amending our Bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive
forum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available
funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the
satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences and
Privileges </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking
fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the right of the holders of shares of any series of preferred stock that we may
designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights under our Investors&#8217; Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and some of the holders of our common stock have entered into an amended and restated investors&#8217; rights agreement. The registration
rights provisions of this agreement provide those holders with demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights with respect to the shares of common stock currently held by them and issuable to them upon
conversion of our preferred stock in connection with our initial public offering. The shares with registration rights are collectively referred to herein as registrable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of registrable securities then outstanding have the right to demand that we file a registration statement covering at
least 40% of the registrable securities then outstanding (or a lesser percent if the aggregate offering price exceeds $15.0&nbsp;million net of certain selling expenses). We are obligated to effect at most two registrations in response to these
demand registration rights. These demand registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified
circumstances. Upon such a request, we are required to effect the registration as soon as practicable, but in any event no later than 60 days after the receipt of such request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders, the holders of registrable securities will each be entitled to notice of the registration and will be entitled to
include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such
registration under specified circumstances, and do not apply to a registration relating to any equity incentive plan, stock purchase or similar plan, a transaction under Rule 145 of the Securities Act, a registration on any form that does not
include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities or a registration related to common stock issued upon conversion of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of at least 15% of the registrable securities then outstanding are entitled to request to have such shares registered by us on a
Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement. These Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights are subject to other specified conditions and limitations, including the condition that the
anticipated aggregate offering price, net of certain selling expenses, is at least $5.0&nbsp;million. Upon receipt of this request, the holders of registrable securities will each be entitled to participate in this registration. We will not be
required to effect such a registration if, within any twelve month period, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses of Registration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required
to pay all expenses, including fees and expenses of one counsel to represent the selling stockholders, relating to any demand, piggyback or Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration, other than underwriting discounts and
commissions, stock transfer taxes and any additional fees of counsel for the selling stockholders, subject to specified conditions and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the
request of a majority of holders of registrable securities to be registered, unless holders of a majority of the registrable securities agree to forfeit their right to one demand registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended and restated investors&#8217; rights agreement contains customary cross-indemnification provisions, pursuant to which we are
obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable registration statement attributable to us, and the selling stockholders are obligated to indemnify us for material misstatements or
omissions in the registration statement attributable to them, subject to certain limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights granted under the investors&#8217; rights agreement will terminate with respect to any particular stockholder upon the
earlier of (i)&nbsp;the closing of a deemed liquidation event, as defined in our Restated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Certificate; (ii)&nbsp;with respect to each stockholder, at such time such stockholder is able to sell all of its shares pursuant to Rule 144 or another similar exemption under the Securities Act
during a three-month period without registration; and (iii)&nbsp;February&nbsp;5, 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Restated Certificate, our board of directors have the authority without further action by our stockholders, to issue up to
10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any
qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific
issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of us
and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders
of common stock until the board of directors determines the specific rights attached to that preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will
fix the designations, voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus
supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of
any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate per share, dividend period and payment dates and method of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including
depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period,
the exchange price, or how it will be calculated, and under what circumstances it may be adjusted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemption rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special United States federal income tax considerations applicable to the
preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the
series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vor is incorporated in Delaware. The DGCL provides that the holders of preferred stock will have the right to vote
separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of
the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable
certificate of designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antitakeover Effects of Provisions of Charter Documents and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested
stockholder, with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#8220;business combination&#8221; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation and the interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or by
any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation
that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#8220;interested
stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate provides for our board of directors to be divided into three classes with staggered three-year terms. Only one class
of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a
majority of the shares of common stock outstanding will be able to elect all of our directors. Our Restated Certificate and our Bylaws also provide that directors may be removed by the stockholders only for cause upon the vote of 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of our outstanding common stock. Furthermore, the authorized number of directors may be changed only by resolution approved by a majority of the board of
directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only be filled by a majority vote of the directors then serving on the board, even though less
than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Restated Certificate and Bylaws our stockholders do not have cumulative voting rights. Because of this, the
holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate and Bylaws also provide that all stockholder actions must be effected at a duly called meeting of stockholders and
will eliminate the right of stockholders to act by written consent without a meeting. Our Bylaws also provide that only the chair of our board, Chief Executive Officer or the board of directors pursuant to a resolution adopted by a majority of the
total number of authorized directors may call a special meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws provides that stockholders seeking to present
proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#8217;s
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate and Bylaws provide that the stockholders cannot amend many of the provisions described above except by a
vote of 662&acirc;&#710;&#8226;3% or more of our outstanding common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in &#8220;&#8212;Preferred Stock&#8221; above,
our Restated Certificate gives our board of directors the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, with any rights, preferences and privileges as they may
designate, including the right to approve an acquisition or other change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combination of these provisions will make it more difficult for our existing
stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also
make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or
other rights or preferences that could impede the success of any attempt to change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance
the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile
takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control
or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased
protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover
proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate provides that the Court of Chancery of the state of Delaware will be the exclusive forum for the following types of
actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising pursuant to the DGCL, our Restated Certificate, or our Bylaws; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&nbsp;22 of the
Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple
jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our Restated Certificate also provide that unless we consent in writing to the selection of an alternative forum, the federal district
courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to
bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our Restated Certificate. This may
require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our Restated Certificate to be
inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate further provides that the federal district courts of the United
States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such
exclusive forum provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150 Royall
Street, Canton, Massachusetts 02021.The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on Nasdaq </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on The Nasdaq Global Select Market under the trading symbol &#8220;VOR&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue
discount&#8221; (&#8220;OID&#8221;), for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued
with OID will be described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and
the terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the
last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the
unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each
issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90&nbsp;days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#8220;Description of Debt Securities&#8212;Consolidation,
Merger or Sale;&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#8220;Description of Debt Securities&#8212;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company (&#8220;DTC&#8221;), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series
are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related
free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or
more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have
summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any
applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed
forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series
of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant
certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as
well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate, properly completed and duly executed at the corporate trust office of the
warrant agent, or any other office, indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the
laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we
discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to
the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have
made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors
in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an
interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a
global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be
registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
legal holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or
has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of
the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the holders, and
not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#8217; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor
depositary, unless special termination situations arise. We describe those situations below under &#8220;&#8212;Special Situations When A Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account
with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the
security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular
security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities
through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#8217;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an
investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When A Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, a global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule
415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or through the facilities of The Nasdaq Global Select Market or any other securities
exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Such at the market
offerings, if any, may be conducted by underwriters acting as principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related
free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement, other than securities covered by any overallotment or other option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change
from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of
securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide
agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these
liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making
at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in
overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to
be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters or
agents who are qualified market makers on The Nasdaq Global Select Market may engage in passive market making transactions in the securities on The Nasdaq Global Select Market in accordance with Rule 103 of Regulation M under the Exchange Act,
during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market
maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be
discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of
the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, GC&amp;H Investments, LLC and GC&amp;H Investments, a California partnership,
which are entities beneficially owned by current and former partners and associates of Cooley LLP, beneficially hold an aggregate of 35,350 shares of our common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements
are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different
information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this
prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file
annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including
Vor. The address of the SEC website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.vorbio.com. Information contained in or accessible
through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus. We have included our website address as an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx904071_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-39979.</FONT> The documents
incorporated by reference into this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are
incorporated by reference into this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;20, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525003259/d861124d8k.htm">January
<U></U>&nbsp;8, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525021763/d921842d8k.htm">February<U></U>&nbsp;6, 2025</A> (to the extent the information in such reports is filed and
not furnished); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock as described in <A HREF="http://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-ex4_3.htm">Exhibit&nbsp;4.3</A> to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> filed with the SEC on March&nbsp;20, 2025, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> as well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any
beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits
which are specifically incorporated by reference into such documents. Requests should be directed to: Vor Biopharma Inc, Attn: Investor Relations,&nbsp;100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140, (617) <FONT
STYLE="white-space:nowrap">655-6580</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus or contained in a document incorporated or deemed
to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be
incorporated by reference into this prospectus, modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g904071g90j12.jpg" ALT="LOGO" STYLE="width:3.73681in;height:1.35986in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $119,699,305 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>August&nbsp;27, 2025 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g904071g51v03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g904071g51v03.jpg
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M ?(# 2(  A$! Q$!_\0 '  !  ,  P$!              8'" ,$!0(!_\0
M1Q   0," @8$!PP* P$!     0 " P0%!A$'$B$Q06$347&!%"(C,D*1H0@5
M%A=2=).QLL'1TC,U56)R@I*BPN$V4_ D0__$ !H! 0 # 0$!
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M1)[8MEHK+2+O: UH V ; B(L4TPB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M D(B( OB>6.G@DFF>V.*-I>][CD&@;22OM5-I\Q3X!:8[%2295-:-><@[6Q
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M]NXX\@K,&P5-"\-KZMIC<P';"X>>?;L[056JX]-2TW*1PZBS^""(B[3D"(B
M(B( B(@)QHFI^DO=5.1F(H,N]Q'W JU5 M$5/JVZOJ,OTDK8_P"D9_Y*>K+U
M+S8S0H6(((B+P/4(B( B(@(#IAPA\)</&HI(\[G1 R19#;(WTF?>.8YK,BVR
MLXZ;L(>\=[]]:*/*WU[B2 -D<N\CL.\=_4M+0W_Y;_L5:*T7U&]T<C7QN+7M
M(+7 Y$$<5\HM0@T2S29%\5YO!>SWV \$Z/KGR\[+JR\;V+/$LCY97R2N+Y'D
MN<XG,DG>2OS6.KJYG5SSR7XO&FB-6=ON,A$5B:&,(?"&_>'5D>M;:%P>X$;)
M)-[6=G$]PXJ]DU7%R8+0T+80^#]A\/K8]6Y5[0YP(VQQ[VMY$[SW#@K%1%\_
M9-V2<F7(OI/N#K9@*]5#':KS!T32.!>0S_)9.6FM.>M\7=;J[NEBS[-<?Z69
M5J>GK^FW^2K"N7W.MC9-5W&]3,#C!E3P$C<XC-Q[<LAWE4TM&>YZ#/@/4:OG
M&NDUNW49]V2]-9)QJ> BS41%B%@B(@(KI/L<=^P7<8"P&>&,U$!RVA[ 3L[1
MF.]906UIPTPR"3S-4ZW8L4G>5J^G2;C*)5A7/[F^X.%5>;<YWBN8RH:.H@ZI
M^MOJ5,*T/<\:WPVJ\MW@#\_I(UTZI9JD0C1*QI?OUY<?G,GVBMEK&E^_7EQ^
M<R?:*X_3NY$LZ*M?W.?_ "JY?,C]MBJA%H6P\D''Y(1ME<554P4D+I:J>*")
MNTOD>&@=Y6*T7!^G?ZO^/_2=Q9VFS&E)B*MI;?:9.EHJ,N<Z8;I)#LV<@,]O
M',JL41=]=:KBHQ("UGHRHGV_ 5D@D&J_P<2$'AKDO_R6>=&F$YL5XABA+'>]
M\!$E5)P#?DY];MWK/!:K:T,:&M #0,@!P"X/4+$\01,3]1$686"(B JC3[2:
MU#::P#S)'Q$_Q $?9*IE:BQAAVGQ-9GT%3(^+QA)'(W;JO (!RXC:=BSQBK#
M%QPU6=!<(O)N/DYV;62#D>OEO6GI+$X[/<O%GB(B+L+!$1 $1$ 7X]P8TN<<
M@%^KSZ^;6=T;3L&_M4I9*MX1W++=335Y,I\A)L</D]14T&T9A5FI=A:X]/#X
M+,[RD8\0GBW_ $IG'W1PW0S]R/>1$7B<H1$0!$1 $12/"N$ZR^O$IS@H@?&F
M</.Y-''ZE$I**RRT8N3PBQ-'%/X/A.E)&3I7/D/]1 ]@"DRX*"DCH:*"E@SZ
M*%@8W/?D.M<ZQYRW2;-&*VI((B*I8(B( B(@"\S$UEIL0V2JME:/)3MR#LMK
M'<'#F"O312FT\H&-;[:JFR7>JMU<S5J*=Y8[J/41R(R([5T%H33KA#WTM0OE
M#'G643<I@T;9(NOM;O[,^H+/:WM/<K8;O<HT$1%[@[=HMU3=KG34%#&9*FH>
M&,;S/$\AO*UMA&PTV&K#2VRDR(B;F]^61D>?.<>T^S(*NM V$/ J%V(:^/*I
MJ6ZM*UP\R/B[M=]7:K=6/K;]\MBZ19((B+A)(KI3H'7' %Z@8,WMAZ89?N.#
M_P#%906UY&-EC?'(T.8X%K@=Q!X+(N-K#)AO$U=;9 >CC?K0N/I1G:T^KV@K
M4]/GPX?W*L\)73[G.],9)<[+*X!TF53"#Q(&J\>K5]15++N6>Y55HN=/7T$A
MBJ8'A['#ZCR(V$+MNK\L'$A&S44,P%I M>*J:.,R,I;H!E)2O=D2>MA](>T<
M5,U@3A*#Q)%PB+SK[>[=8J)U7=JN*FA&[6.UQZFC>3R"A)MX0/+TD7IEBP;<
MJISPV5\1AA'$R/! R[-I[BLEJ9Z3,<3XPN3>C:Z&V4Y/00D[2>+W<S[!WYPQ
M;>DI=4.>V4;"N7W-] YUPO-P(\5D3(&GK+CK'[(]:IK?N6JM%.'G8<P;2P3L
MU:NH_P#HG!WASMP[@ .W-5UL]M6/DE$O6-+]^O+C\YD^T5LM8TOWZ\N/SF3[
M17/Z=W(,Z*(K(T&6:W7K$5?!=:.*KB92%[6R#,!VNT9^TK1LFJXN3]B"MT6K
MJG1YA:>GEB]Y:6/7:6Z\;<G-S&\'@5FG%M@J<-7ZIMM8,W1G.-^60D8?-<.W
MZ\PO&C4QN;2#1XZG6C;1[-C R5+ZR*FH(7ZDNJ=:4G?D&\.T^U052G1QBN7"
M>(8ZK-SJ*7*.JC'I,SWCF-X[QQ7I;OV/9V$:>P[8Z##ULCH+5 (8&[3Q<\\7
M./$KTEQTL\55315%/(V2&5H>Q[3F'-(S!"Y%\^VV\LN$1% "(B +JW.WTMSH
MI*2O@9/3R#)S'CV\CS7:1$\= H3'FC>KLG25MIUZNVCQG-RSDA'/K'/U]:KU
M:]5:8]T9P7+I*ZP-935I\9\&Z.4\ODGV=F]:%&K_ (V?[EE+Y*-1<];25%#5
M24U9"^&>,Y.8\9$%<"[RX1%^.<&M+G'(!"#AJYNBCV>>=R\I<D\AED+CW#J7
M&O6*PCQD\L+DIYGT\[)8CD]AS!7&BL5+#MU6RMI&31\=A'4>(794(P]<? :K
M5D/D)-CN1X%3=<\H[6<5D-C"(BH>87ZQKGO#6-+G$Y  9DE=RT6NKNU6VGH8
MC(\[SP:.LG@%;>%,)4EC8V63*HKB-LI&QO)HX=N]>5MT:USV>M=3F1S". R=
M2KOC<AO;3?F_#U]2L>-C8V-9&T-8T9!K1D %^HLVRR5CRSMA!06$$1%YEPB(
M@"(B (B( B(@/QS0]I:X!S2,B#N(67-*V$CA;$;Q3L(MM5G+3'@WK9W'V$+4
MBCN/L,PXJPY44$FJVH'E*>0^A(-W<=QY%=.EN\4^>F0T9(4NT8X4?BO$D<$C
M3X!3Y2U3Q\G/8WM=N[,SP4:DH*J.Y.H'P2"L;+T)AR\;7SRU<NO-:HT<86CP
MIAN&D(::R3RM3(/2>>'8-P]?%:>JO\4..V0D2:*-D43(XFAD; &M:T9  ;@%
M](BPRP1$0!0'2W@GX56AM10M NU("8N'2MWEA^L<^TJ?(KPFZY*408IFB?#*
M^*9CF2,):YKAD6D;P0OA:8TCZ-:+%.O6T+F4=WR_29>)-R>!Q_>W]JSYB'#U
MTP]5FGN]')3NS\5Q&;'\VNW%;=&HA<N.RC1Y8):002"-H(4EMN/,3VV,,I;U
M5Z@V!LI$H']0*C*+VE&,N)+()C4Z3,75#"Q]YE:#_P!<;&'UAN:BU=755PJ#
M/75,U3,=[YGE[O65UT41A&/[5@!%R4T$U3.R&FBDFF><FLC:7.<>H *X-'VB
M"::2*NQ6WHH1DYM$#XS_ .,C<.0V]BK;=&I9DPEDZ&A; C[M717RZ1$6ZG=K
M0,</T\@._P#A!]9V=:T(OB"*."%D,$;8XF-#6L8,@T#< %]K$ON=TMS+)8"Q
MI?OUY<?G,GVBMEK&E^_7EQ^<R?:*[/3NY$,Z*M?W.?\ RJY?,C]MBJA6O[G/
M_E5R^9'[;%V:K_"D0C02@6E_!PQ-8344<>=TH@7Q9#;(WTF?>.?:IZBQ*YNN
M2E$N8F(()!&1"*U-..#?>FY^_=OCRH:Q_EFM&R*4[<^QV_MSY*JUOU6*R*DB
MA=>@;&>J[X-W&38<W4;W'CO,?UD=XZE=RQ53S24\\<T#W1RQN#V/:<BT@Y@A
M:IT:8MCQ9AYD[BUM?!E'51C@[@X#J=O]8X+-UM&U^2/3+)DL1$6>2$1$ 1$0
M!$1 1W&&$;=B>EU:MG1U31E%4L'CLY'K'(^Q4%BS"UQPS6=%7QZT+CY*=FUD
M@[>!Y%:?76N-#2W*CDI:Z!D]/(,G,>,P?]\UT4ZB5?#Y1*>#):\^OFUG=&T[
M!O[59^D?1U5V*":X64255O&US,LY(!UGK:.OU]:J1:],HV+=$2E[!$1>YYA$
M1 %+\+W'PB#P69WE8QXI/I-_TH@N>B?-'5PNI0YTVL-1K1F2>K+CFJR644G#
M<L%BJ2X4PE5WQS9I,Z>A!VRD;7<FCCV[E[^"L#%\$%=?XBQ[FAPHSZ/\?X>O
MJ5D,:UC UC0UH&0 &0 65=J<?; \JZ,\R.G:+726FD;3T,0C8-YXN/63Q*[J
M(N%MOEG6ECA!$10 B(@"(B (B( B(@"(B (B(",28+MDF-F8E+/_ *FQ:O1Y
M>*9-PD[=79ZBI.B*TI.78"(BJ B(@"(B +@K:.FKJ=]/6T\51 _SHY6!S3W%
M<Z)T"NKUH?PS<'.?2LJ+?(=OD),VY_PNS]F2BU5H*=K$TM^:6\!)3?>'*[D7
M1'56QZD1@HN+055%WE;["UO[M.2?M!>[:]"-F@<'7&OK*PCT6 1-/;O/M5KH
MI>KN?\AA'D6##5GL$>I:+?!3$C(O:,WN[7':?6O71%SMMO+)"(B@!0"IT287
MJ:F6>6*KZ25Y>[*<[R<SP4_17A9*'[7@%=_$[A7_ *JSZ<_@O;PG@6S86K9J
MJTLG;-+'T3NDDUAJY@_<%*45I7626'(8"(B\@=.\6VEO%LJ*"X1"6FG;J/;]
MXZB-X*@_Q.X5_P"JL^G/X*Q$5X6SAQ%X!7?Q.X5_ZJSZ<_@O9PM@*SX8KWU=
MI-7'(]AC>U\VLUPYA2M%9W626'(8"(B\@$1$ 1$0!$1 $1$ 51:2M%$5?TMS
MPQ&R&KVNDI!L9+S9\EW+<>7&W47I5;*IYB#%51!+33R0U$;XIHW%KV/&3FD<
M"%QK4FD+1];\6P.F;JTMU:W)E2T>=U->.(Y[Q[%F[$5BN&'KD^ANM.Z&9NT'
M>UX^4T\0MJC4QN7Y*-'F(BDV!\%W/%U;T=$SHJ1A\M5/'B,Y#K/(>Q>TI**S
M+H'CV2TUU[N,=#:Z=]14R;FMX#K)X#F5HW1SHXH<+1LJZS4J[N1ME(\6+DP'
MZ]_8I!@_"ELPK;A36R+QW9=+._:^4]9/5RW!>\LC4:MV?;'A%D@B(N(D(B(
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*B( B(@"(B __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g904071g65s86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g904071g65s86.jpg
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ME3O]$5/K5UPJ,O(C;'G_ %+G_B59IU24\4;O"30 9;1
M
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MH^+[%-AS$5;;)\U2%_BWKY[%VM=Z/7F:O!R]5>B?9"T>[3@ T$
M ?=/#)43QPP,5\LCD8QJ;W*JY(B%M<"X?CPSAFCMS$196MUYG)YTB^4OL3@B
M$,Z!<,]\;Y)>:EF=-0;(LTV.E5-GS4V]:H6$,KG9=SZ<>RRL>X #/2
MYO'=\[SV9R0NRJZC..++>WI=V?:J'12/;'&Y\CD:QJ*YSEW(B<Y!V++RZ]WB
M6HS5(&^!"U>9J?CO[2_!CZ[=_$*<U^BO;RTY^ &D\           !*NB:GU+
M)53JFV6?+L1$_%2*B:]'\'<^$Z%%3:]'2+VN7+U9'GY4ZII?QXW=T( ,Y[@
M
M                                                  '"Z::7NC T
M\F6:T\T<OKU?\BO):3'5+W;@^\0Y9JM,]R)Q:FLGK0JV;'P^V\<Q^[L  />Z
M          #ZC>Z-[7QN5KVJBM<BY*BISEF-'F(VXEP[#4/<G=D7BJAJ?MIS
M]2IM]/05E.MT9XE7#F(HW3/5*&IRBJ$YD3/8[L7U9GEY>'U:=O,$K)@(J*B*
MBHJ+M14!A(@     13I[PSW?9HKW2LSJ*'P9LDVNB5=_]JKGU*I*QYU,$553
M2T]0Q)(96JQ[5W.:J9*A9BR3CO%H<F-J6@WF-K!+AK$E9;9,U9&[6A>OGQKM
M:OHV+Q131F_6T6C<*@ $@     #UI*>6KJH:>G8LDTKTC8Q-[G*N2(>1+&@+
M#/=UWFOE4S.GHO AS38Z54VK_:B^E4Z"O+DC'2;2[$;3'@NPQ8;PW1VV+)71
MLSE>GGR+M<OI]61NP#Y^TS:=RM  <    #%NE=#;;?/5U*Y11-UEX]")Q5=@
MB-]CPX_2??.YJ-MKIW>-G36E5/-9T=OV)Q(M,NZ5TURN$]74+G)*[67@G,B<
M$388AJXL?IUTSLE^NVP %BL           L#9X.Y;31099<E"QB]C4()M,'=
M5THZ?+/E9F,]*Y%@3Q\N?$/7QH\R  \3U
M
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MED7L:JIZ\B;"*=$]/RE]J9E39% J=JJGL125C/Y4[OI[N/&J  /,O
M
M                                             "ONFRE[GQL^7+94
M01R>C-O^)8(AOW0%+E4V>K1/*9)$Y>I45/O*>S@VUEB/N["(P ;;H
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MU>@JS9(QTFTNQ&TPX7LT&'[#1VRFR5D#$179>6[>YW:N:FT ,"9F9W*T !P
M   .3TBWSO9:5I8'9554BM3+>UG.OL_\$J5F\ZA&UHK&Y<)CR^=^+PYL+LZ2
MGSCCRW.7G=V_8B'- &K6L5C4,ZUIM.Y  21             $F:(H,J2XU&7
ME/;&B]2*O^2$@'*Z,H.1PK$_+;-(^3UZO^)U1EYIW>6CBC5(  5+
M
M                                             CC3K2\MA.GG1-L%
M4U57@K7)]N1(YRVD^E[KP)=V(F:LC25/[7([[$4NX]NG)6?W(5H !]"D
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MON>F  'J>8              #T@C6:>.)OE/<C4ZU7(.ITPK3]S8<ML662I
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MI^453G+3YKND1/";VHF?]O$\_)XE*TZJ1X=K;[IX !F)@
M.:Q[BVFPA:&5E1$M1)+(D<4+7:JN7>JY]")[.DC_ -_.G_D4OUE/RG"Z7L2_
MI%BR9L#]:AHLX(<EV.5%\)W:OJ1#B#6P\.G1$WCNA-DX^_G3_P BE^LI^4>_
MG3_R*7ZRGY2#@6_)X?M_USJE./OYT_\ (I?K*?E'OYT_\BE^LI^4@X#Y/#]O
M^G5*<??SI_Y%+]93\H]_.G_D4OUE/RD' ?)X?M_TZI3C[^=/_(I?K*?E.TT>
MXV=C)M5)%:Y*2FI\FK*^5'(YZ^:FQ.;:O6G25CME#/<KA3T5'&LE1.](V-3G
M55+:X1L4&&\/TELILE2)N;WY>6]?*=VKZLCR<K%BQ5U6.\NUF9;@ &>F
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MLTY9KEZF^%[#4'6Z,*?EL4-DR_4PO?\ 8W_(ADG5)E.D;M$)? !DM(
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M !3M)H/"@I(*"B@I*2-(Z>!B1QL3F:B9(>Y@YLLY;S:5L1H !4Z
M                                                    *X:7*7N7
M'EQR3)LR,E3M8F?K13CB3]/=+R>(+?5(FR:FU.M6N7\R$8'T'&MU8JS^R4
M+P               !GV&Z5%EN]+<*1<IH'HY$YG)SHO!4S3M+266Y4]XM5-
M7T;M:&=B/3I3I1>*+L*F$IZ$<3=R5S['5OR@J5UZ=57R9.=O:GK3B>'FX>NO
M7'F')3: #&<     '&:4<'_I;988J=6,KJ>5'1/=NU55$>B\,MO6U#I[-;J>
MT6JEM]&W5@IXTC:G3ESKQ7>9@)S>TUBGM!H !     /QSD:U7.5$:B9JJ\P&
MAQK>TLMFD?&Y$JIO%PIT+SN[/P(3555555557:JJ;S&5Z6]WF25BKW-'XN%/
MB]/;O]!HC3P8^BO?R\&6_7;]@ %RD                )#T109S7*H5/):R
M-%ZU55^Q"/"6=%,')X?FE5-LLZ^A$1/MS*.1.L<KL$;N[, &:]X
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M '*J^TA%$S7)"P=N@[EM]- FSDHFL]"9'DY<_3$/3QH[S+( !X7L
M   .!TQX4_2+#;JBECUKC0HLL62;7L\YGH3-.*<3O@3QWFEHM I2#O\ 3)A3
M]'L1NJ:6/5MU>JR1Y)L8_P YGKS3@O X W\=XR5BT*@ $W   #TI9Y:6IBJ*
M=ZQS1/1['IO:Y%S13S!P6ZP5?HL2X;H[E'DCY&ZLK$\R1-CD]/J5#>%>] N)
M>]M^DL]2_*EK]L>:[&S)N^<FSK1"PAA<C%Z5YCV6Q.X  4.@     <#IFQ-W
MAPJ^GIWZM=<,X8\M[6>>[T+EUJAWRJC457*B(FU54JII.Q*N)L5U-3&]5HX?
M$4R<VHB^5VKFO:AZN)B]2^Y\0C:=0Y0 &VK      ^X(I)YHX86.?+(Y&,:U
M,U<JKDB(?!+>@7"G=MQDO];'G3TBZE.CDV.EYW?VIZUX%>7)&.DVEV(VE;1Y
MAF/"V&:>BR:M4_QM2]/.D7?V)N3J.E ,"UIM,VE:  B 5<DS7<>%?64]OHYJ
MNMF9!31-UGR/7)$0KSI(TG5>('2T%H=)2VGR7*FR2=/C=#>'IZ$NPX+9IU'A
MR9T[['6EJ@L[I*.Q(RX5S=BR9^)C7K3REX)LXD&X@Q!=,05:U%WK)*A_FM5<
MFLX-:FQ#5 V,/'IBCMY5S.P %[@          !WF"])UZP\L<%2];A;TV<C,
M[PFI\5V].I<T.#!"]*WC5HV[$Z6XPEBVTXII.6M<^<C4\9 _9)'UIT<4V&^*
M96RX5=KK8JNWU$E/4QKFV1BY*G_;@6&T9Z2Z?$:1V^[:E-=T3)J[F3_T]#N'
MHZ$RN1Q)Q_53O"<6VD< 'B2     &NQ)\';K\DE^XXIT7%Q)\';K\DE^XXIT
M:GP_Q9"P #10             'ZQ[HWM>QRM<U<T5%R5%)&P;I8O%E<R"ZJZ
MYT*;/&.\:Q.#N?J7TH1P"%\=<D:M#L3I;_#.([9B6@2JM-2V5J;'L78^->AS
M>;[#;E.K!>J^PW&.NM=0Z&=G1N<G[+DYTX%F-'F-:/%]M5S$;#<(43NBGSW?
M&;TM7U;NO(Y'%G%]5>\)Q;;K0 >1(     :C%]+W;A:[T^6:OI9-5.*-54]:
M%5BW[FHYJM<F;53)4*D7"G6CKZFF=Y4,KHU[%5/8:GPZW:U788X --T
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M8<F=-+I,QW4XLKUAIU?#:(7>*ASR5Z_MNX]"<WI.( -RE(I'356  FX
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MEDCIUE3^]$=[2S9 6G*EY#&+)D3944S'JO%%<W[$0]WP^VLDQ]X=A'@ -ET
M                    3-H/Q-RD,E@JW^''G)2JJ[V^<SLWIUKT$M%2;973
MVVX4];2/U)X'H]B\4]A:/#5X@OUDI;C3+X,S?";GM8Y-BM7J4Q^=AZ+=<>)<
MELP >!P     "'=(5\[ZW=8('YTE*JL;EN<[G=[.SB=WC^^=Z+.Z.%V574YL
MCRWM3G=_OG4AH]G%Q_GEY>1?\L  /:\@                     [K1+3Z]
MWK)U39'#J]KG)^524C@]$<&K;:^HR_62HSYJ9_Y'>&9R)WDEH8(U2  %*T
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MHKG.5<D1$YRI^D/$;L3XIJZY'+W,B\E3M7FC;N].U>T]?#Q>I?<^(1M.H<V
M#:5@     =/HYPP_%.)H*-4<E)'XVI>G-&B[NM=W;P.81%541$S52T.B;"J8
M9PRSNAF5QK,IJC/>W]EG8GK53S<G-Z5.WF4JQMV<,;(8F11,:R-C4:UK4R1$
M3<B'T 8:P /Q[FL8Y[W(UK4S55W(@' :9<6KAW#W<E')JW&N18V*B[8V><_V
M)Q7@5I.CT@XA?B;%-97ZRK3H[DJ=%YHVYY>G?UJ<X;O&P^E37O*N9V  ]"(
M  /2F@EJJB."FC?+-(Y&L8Q,U<J[D1"=]'VB2FHHXZ[%#&U-6N3FTF><<?\
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MO0KSI%T=UN%)%JH%=5VERY-F1/"CSW(]/;N7AN-#!RZY?IGM*$UTX4 'K1
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MWJ\352YI%Y$35\UB;OQ[34 &K$16-0S9G<[D !UP
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M*;:S+-$EU_FHKO8<M.HF4JQN8A.#41K4:FQ$3)#] ,=I@
M     "O&G/"G>F]I>*./*BKW+RB(FQDV]?G;^O,C N#BFR4^(;%5VRK3P)F9
M-=EM8Y/)<G4N14F[6^HM5RJ:"M9J5%.]8WIQ3G3ASFQP\WJ4Z9\PKM&F( #V
MH@  'ZURL<CFJJ.1<T5-Z*?@ M=HUQ(F)\*TU6]R+5Q^)J4_]Q$W]J9+VG,:
M=\3=Z\/LM%,_*JN&:/R7:V%-_I79U9D;:&\5LPYB-T-;*D=NK6ZDKG+L8Y/)
M=]J=O Y['%_DQ+B6LN3\TC>[5A8OFQIL:GM7BJF;3BZS[]H[I]79H@ :2
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MFJGQ5<JIZE0TQV^F.E[FQW6/1,DGCCE3YNJOK:IQ!]'AMU4B?V2  6
M                &SPU>)[#>J6XTJ^'"[-S<]CV\[5ZT-8#DQ$QJ1;>UUT%
MSMU/6TC]>"=B/8O!?::W%]Z;9+-+.U4[H?X$+5YW+S]F\C30AB?D9I+#6291
MR9RTRN7<[>YO;O\ 3TGGCB]]^;R]8G9TD&<<70O2[M^S(Q?EIKEFL^(49K]%
M7/O<Y[W/>JN<Y<U5=ZJ?(![6>                        '8Z+(.5Q(^5
M4V0P.=VJJ)[5..)'T0T^RY5"I^Q&B^E5]A5GG6.5N&-WA(H ,MH
M             0WI]PIRU/'B*BC\9$B15:-3>W<U_9N7@J=!,AY5E-#64LU-
M4QMD@F8K'L=N<U4R5"S#DG%>+0Y,;4N!OL<X=FPOB.JMTNLZ)%UX)%\^-?)7
MV+Q130F_6T6C<*@ $@            [71-A5<38F9W0S6MU'E-49IL=M\%G:
MJ>A%(7O%*S:?9V$LZ$L*=Y,/]\JN/*ON"([)4VLB\U.W>O9T$D!$1$R38B P
M,EYR6FTK8C0 "   #$O+UCM%<]%R5L#U]#5*:%R[PQ9+371IO= ]OI:I30T_
MA_BR%@ &D@  #8X:C27$5JC=N?5Q-7M>A<4IUAN1(<0VN5VYE5$Y>QZ%Q3+^
M(>:IT  9R8          !'^G2-'Z/:IR_P#+FB<GSLO:2 1_IUE2/1]4M7_F
M3Q-3YV?L+<'XE?\ ;D^%:0 ?0*@  "1] +U;CM43SJ21%]+5]A'!)&@%BNQV
MY4\RDD7UM3VE'(_"M_IV/*QP ,%:UV)/@[=?DDOW'%.BXN)/@[=?DDOW'%.C
M4^'^+(6  :*                  9MFME5>;G3T%OB66IG=JM:GK5>A$WJI
MR9U&Y'>Z"L..NN)^^<[%6DMWAHJIL=*ODIV;5[$Z2QAI,&X>I\,6"GMM+DY6
M)K2R9;9'KO=^'!$-V87(R^K??LMB-0  H=     $)Z?J74N]JJ\OUL#HL_Z7
M9_YD5DY:>J7E,.T%4B9K#4ZG4CFK[6H0:;O"MO#"4  /4
M        ?CE1K55=R ?$M2^F5KX7JV5%S:Y-Z<3KK76-KJ-DS<D=N<G0IP,K
MUD>KE[#98>N'<59JR+E#+X+N"\RE62O5#RYHZXV[8 'F>(
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M:[$GP=NOR27[CBG1<7$GP=NOR27[CBG1J?#_ !9"P #10
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M*;DCR@JGT=5'-'O:NU.E.=#OZ>9E1 R6)<V/3-#SY*ZG;RY:=,[AZ  K5
M                  #Z8U7N1K4S55R1"PM)"E/2PPMW1L:Q.Q,B,L$X-FJI
M(:^Y(Z&G:J/CCW.DRVHJ]"?:2D>#DWBTQ$>SV\>DQ$S( #RO0
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MC<W\N3_UV)06#UJ:>:EJ)(*F)\4T:ZKV/3)6KT*AY&HZ
M &/62ZK-1-Z[^H.3.H8U3+RDFSR4V(>0!%3Y  ' Z#"MPY.5:25? >N;%7F7
MH[3GS]:Y6N1S55'(N:*G,1M&XTY:O5&DD@P;-7)7T39%RY1O@O3B9QYIC79X
MIC4ZD !QP              #-M-LJKK6-IJ&)9)%W]#4Z57F03.N\NQ&_#%A
MBDGE9%"QSY'KDUK4S55)/P=@B.BU*R[M;)4[V0[VQ]?2OJ-SA3"U+8HD>N4U
M:Y/"F5-W!O0GVG0G@S<CJ^FOA[,6#7>P #RO0
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M RY)R7FTK8C0 "MUKL2?!VZ_))?N.*=%Q<2?!VZ_))?N.*=&I\/\60L  T4
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M1ZJ;W/7:YZ]*J9=+3PTM.R"FC;%$Q,FL:F2(AZF=ES3D_P!/=CQ13_8 "E:
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MS3BMU0Y,;4M!W^E'1_/A:K=64+7RV:5W@OWK"J^8[AT+[3@#<I>N2O557K0
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MLO3$?-O93KM1O%W2O [[=N ,Z]YO.Y>ZE(I&H  02
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MY"C9M7RY'>4]>*^PV0!X)F9G<O9$1':  ''0
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M\@\]^=DM_;V=BL.9PQ@:PX;U7V^B:ZI3_P#(F\.3L5=W8B'3 'DM:;3NTI
M(@       ##O-.^KL]=3PHBRS0/C;FN29JU43[2N_O08K_<4GUA"R@+\/(MA
MW%7)C:M?O08K_<4GUA![T&*_W%)]80LH"[Y[+^SG3"M?O08K_<4GUA![T&*_
MW%)]80LH!\]E_8Z81#HCP%>\,8FGK;K' V!]*Z)%9*CEUE<U=W8I+P!YLN6<
MMNJSL1H !6Z   8MUH*>Z6VIH:UB24]0Q8WMX+[3* B==X%<:S0[B6.KF92M
MI98&O5(Y%F1JN;GL54YMAX^]!BO]Q2?6$+* ]GSV7]D>F%:_>@Q7^XI/K"#W
MH,5_N*3ZPA90'?GLO['3"M?O08K_ '%)]80>]!BO]Q2?6$+* ?/9?V.F' X'
MAQ98L/P6VXVV&L= JMBD;5-3*/F:N?1M3JR!WP/-;)U3N8AW0 "MT
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M81$1$1$R1-R( #R/2
M
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M=39F-R.3.7M'A.*Z  >5(
M
M
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M="'T8V;/;-.Y\+(C0 "AT
M
M
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MF2V2>JRR(T  K=
M
M
M        CK29HVIL2,DK[6C*:\(F:\S)^#NA?C>GA(H)X\EL<]528VIC<**I
MMU9+25T+X*F)VJ^-Z9*BFQPKANXXGN;:*UPZSM\DCMC(F]+E_P!JI8'2WAFV
M7?#\U?4PJVMI43DYH\D<J9Y:J[-J;3IL+V"WX=M4=%:X$CC1$5SEVND=^TY>
M=32MS?\ Y]41W0Z>[7X&P;;L(V_DJ1O*U<B)RU2Y/">O0G0WA]ITP!F6M-IW
M9, !$
M
8                             ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g904071g90j12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g904071g90j12.jpg
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M=(*2E+&R%U)BHL+2,T-R@_ DD^$T4U3Q1$5C_\0 &@$!  (# 0
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M5^6(K>8J[,<S-8F0 &M,
M
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MLB_:55]IGCSVV#FMNI:?++DHFL]"9'H*:T[M,K2L:B(  19
M
M                                       "K>,Z7F6++O B9-;52*U/
MX5<JIZE0M(5XTQTO-L=5;T3))XXY4^[J_FU3LX4ZO,)5:2 "S3
M )JT)8FYS1R6.K?G-3HKZ=57QF=+>Y?4O A4]EFN,]INE-7TCM6>!Z/;U+UH
MO!4V&K-C[E9JQ,;6Q!X+#=(+U:*6X4BYQ3LULNEJ]+5XHN:'O*:8U.I:P &
M   Q&+K'#B+#U;;*C).69X#U\AZ;6N[ER,N#,3-9W I;74LU#63TM4Q8YX'K
M'(U>AR+DJ>HZ"7OA 89YI<X+]2LRAJ\HJC+HD1-B]Z)_+Q(A/08<D9:1:$
M&T        >JU4$]TN--0T;->HJ)$C8G%5R]!;W#5G@L-CH[92I\W3QHW6RR
MUG;U<O%5S7O(>^#YAGE:BIQ#5,\&+."ES3RE\=W<FSO7J)S*CG9>JW1'B$H@
M !P,@     :-I/OG-:)MLIWY35"9RJB^*SJ[_P D7K-PN5;#;J">KJ7911-5
MR\>"<5W$#7:OFN=QGK*A<Y)79Y=2=")V(=7%Q=5NJ?$-&>_3&H]WD !8N$
M         ]UCI^=7FA@RS22=C5[-;:>$V/1Y3\OBRBS3-(]:1>YJY>O(C>=5
MF4J1NT0FH %,LP
M
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MJ^HR\>5K,_\ 2F?]1IY$ZQRVX8W>&_  JE@
M
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MLD "N=@
M
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M188CK+_75=55UF4K63R*[DH_)3;N5=Z]J=1NAPWKTVFN]L@ (@
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M9)DFX %(D
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M2=G209QQ=2];N]?5D;L&/N6]?#5EOT5_]:Z]SGO<]ZJYSES55WJI\ +57@
M                EO153\EAR254VS3N=GP1$3V*;D8/!%/S;"MN9EDKH^4^
M\JN]IG"HRSN\RLL<:K$  -:8       #$8LL5/B.P5=LJLD;,WP'Y;6/3:UR
M=BE1[I05%LN-30UC%CJ*=ZQO;Q3V%SR%]/\ A37BCQ'11^$S**K1$WIN:_\
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MYTM.Y-NHY^;_ +J;?4:1=--&':95;10UM:Y-RMC1C5[W+GZC93#>_P!L&TG
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MJJD5NS>UG2O?N]/41"9'$-TDO%VGK)<T1ZY,;^ZU-R&.+;#C[==>ZNRWZ[;
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ME*P .)D     #&XG^C5V^J2_H4R1C<3_ $:NWU27]"DJ_= IP #TB
M    !RCD?$]'QO<QR;E:N2H<0!M5ET@8GM"M2FN]1)&G^74+RK<NKPL\N[(D
M?#>FZ-ZMBQ%;^3SV+/2KFG>Q=OH5>P@X&B_'QW\P;7(L=\ME]I><6BMAJHNG
M47:W@Y-Z+VF1*96JYUMIK&5=LJI::H9N?&[)>Q>M."D[:.M+-/=GQ6_$?)TM
M<[)K*A-D4J]2_NKZEX;BMS\*V/ZJ^L)1*5P <3(        5\TSTO-\<3R99
M)40QR^K5_I+!D,Z?:75K[35HGCQ/B5?]*HJ?J4ZN).LC-?**  6K8
M            2WH0Q-J226"K?X+LY:557<N]S/;Z2)#NHJF:BJX:FF>L<\+T
M>QR="HN:&O+CC)6:RQ,;6W!A\(WR'$-AIKA#DCGIJRL3R'IXR?\ .A4,P4LQ
M,3J6L !@        ".M*=\R:RT4[MJY/G5/Y6^WT&[7VYQ6BUSUDV2I&G@M_
M>=T(0/65,M952U-0Y7RRN5SEXJ=?%Q=4]4^SGSWU'3#I !8.(
M        V;1Q3\OBRE54S2)'R+]U43UJAK)OFB.GUKK75&7^'"C/O.S_ *37
MFG6.9;,4;O"40 5"Q             !=J9*5>TN84^3.)GNIF:MNK,YH,DV-
M7/PF=RKZ%0M":SI%PQ'BK#-119-2J9\[3/7R9$W)V+N7M.GBYNU?U\2Q,*F
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MPQ,NZ^7BNOEREKKI4.GJ)-ZKN:G0B)T)P,> 7$1$1J$0 &0
M  !*FB[2?-9GQ6N_R.FMBY-CF7:^G][?6G1U%@H98YX62PO;)$]J.:]JYHY%
MW*BE*24M#VD%UDJ8[/>)56URNRBD<O\ Z=RK^E>GJW]97<KB=7UT\LQ*PX"*
MBIFFU 520  !C<3_ $:NWU27]"F2,;B?Z-7;ZI+^A25?N@4X !Z1
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M=G34JY.RW.DZ?1N])II]555555557:JJ?"WI2*5BL*VUIM.Y  21
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MDJ*;,62<5XM I2#9=(6&9,+8FJ:%4<M,[YVG>OE1KN[TW+V&M'H*VBT1:$
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M*<  ](@   25\'[Z=O\ J<GYM(U)*^#]].W_ %.3\VFCD?RK?V(6/ !0)@
M'":*.>%\4S&R12-5KF.3-'(N]%0Y@"IFD;#R89Q964$:+S9526!5_P#;=N3N
M7-.XUDF'X2$#&W:RSHB:[X)&+V-<BI^I2'CT''O-\<6E"0 &X  !8;X.]4LN
M$:VG<N?(5:JG!'-:OYHI*9#7P;7*M#?6="21+Z4=[B92AY4:RV2CP  YV0
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M\&Y5"IO5D:+Z57V$BFH:+:?DL,K(J;9IG.[DR;[#;RJSSO)*QPQJD  -+8
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ML+6V/++.)'_>\+VF9.JDA2GI886[HV(Q.Y,CM*6T[F96E8U&@ &&0
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M;3U,?CPR-D;VHN9&T;K,"Z0.JCJ&5=)#40KG',QLC5ZT5,T.T\VF
M     (R^$),D>"((\]LM8QOH:]?85S)K^$A<$5UFMS5VHCZAZ>AK?R<0H7?"
MKK%",@ .M@  $G?!ZC5^-JE_0RB>O\[$+%D$_!NI=:YWJKRV1PQQ9_ZG*O\
M03L4G-G>64H\!C<3_1J[?5)?T*9(QN)_HU=OJDOZ%.:OW0RIP #TB
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M+=#EFCIV9]B+FOJ0QIM&C6#EL5T[LLTA8^1?1E[2.2=5F4Z1NT0F4 %,L@
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MQ>MJ]"E?\=8(KL,3K(FM46URY,J$3Q>#TZ%]2EI@Y,9/2WE.)VU( '4D
M               8VNFUY-1J^"WUJ>NLFY*+9XSMB&*)TCW:[S[  -C6&6PY
M<.9UG)R+E#+L7@O0IB08F-QI&8B8U*3 8?#5PYW2<E(N<T6Q>*="F8.:8U.G
M#:O3.I  81                 #/X6PQ5WZ?-B+%1M7PYE39V)UJ8M:*QN4
MHB;3J&.LUJJ[Q6-IJ&)7OWN<NQK$ZU7H)APKAFEL$"JSYVK>F4DRIOX)U(9"
MS6JDL]&VFH8D8S>YR[7/7K5>E3W%;FY$Y/2/#MQ88IZSY  <[<
M                 5VTZ84^*+XEXHX\J*O<JR(B;&3;U^]O[<RQ)B<56.GQ
M%8:NV5>QLS/!?EM8]-K7)V+D;^/F[5]^S$PIX#UW6WU%KN530UK%944[UC>W
MBGL/(7T3OUA$ !D   .<,3YYHXH6.?+(Y&M:U,U<J[$1#@2UH$PISZYOOU9'
MG34:ZE.BIL=+TK]E/6J=1KRY(QTFTD)9T=89CPKAFGHLFK5/^=J7IY4B[T[$
MV(G8;, >?M:;3-I3  1        &@Z;+"MYP7-/"S6J;>[G+,MZM38]/1M^R
M5D+L/8V1CF/:CF.3)47<J%3-(>''X8Q35T.JO-E7E:=R^5&N[T;4[BT_A^7T
MG'*,M: !9,   $X:&=(C%BAP_?9D:]N3*2H>NQ4Z(W+U]2]W5G!X-6;%7+7I
ML1Z+L@KWH_TMU5HCCH,0MDK:%N363HN<L:<<_&3U]NXG*Q7ZV7ZE2>T5L-5'
MEM1CO";_ *FKM3O*7+Q[XI]8]$HG;)  T,@   ^.<C&JYRHUJ)FJJN2(1WC/
M2O9K(R2"V/;<Z]-B-B=\TQ?XG]/8F?<3ICMDG58&V8LQ)088M,E=<I,D39'$
MB^'*[]UJ?\R*KXKQ!68FO4]QN#O#?L8Q%\&-B;FIP_\ *G'$N(+CB.XNK;M4
M++*NQK4V-C3J:G0AB2XXW&C#&Y\HS( #K8   -RT26%;]C6B8]FM34J\YFZL
MFKL3O=DGI--+*:$,,K9,+\]J6:M;<<I514VMC3Q$]:KW\#FY67MXY_,D)% !
M1)AC<3_1J[?5)?T*9(QN)_HU=OJDOZ%)5^Z!3@ 'I$   "2O@_?3M_U.3\VD
M:DE?!^^G;_J<GYM-'(_E6_L0L> "@38/&F'H,3X>JK;49-<]-:*14_PY$\5W
MOX*I4JXT4]NKJBCK(UCJ('K'(U>A47(NB0OI]PCRD;<24,?ALRCK$:F]-S7]
MVY>[J._@Y^FW1/B6)A!P +=$  '**1\4K)(G.9(Q4<US5R5%3<J%JM&6*V8K
MPW%42.3G\&454Q/WNAW8Y-OI3H*IFU:-L5284Q)%5.5RT4OS52Q.EBKORZTW
M^E.DY>5@[M/3S!$K7@X0RQSPQRPO:^*1J.:YJYHY%W*AS*-,
M #KJ((JF"2&HC9+#(FJ]CTS1R=2H=@ @_2%HUEMO*W"P,?-1>-)3IM?%Q3K;
MZTXD9%O2,](6C:*Y<K<+"QD-=XTE/N9+Q3J=ZEX;SOP<K^F_^THM^4' [*F"
M6FGD@J(WQ31KJO8],E:O4J'66"8             'Q51$55V(A]/#<)O\IJ\
M7&8C;$SJ'EJ)5ED5R[NA.!U@&UH  9   >FW5;Z*K9,S;DOA)UITH2!!*R>%
MDL:YL>F:*1L;'A.X:KEHY5V.VQJO0O2AKR5W&VC-3<;AM( -#D
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MBDMU$W6GJ'HQ.IJ=*KP1,U[BW6'[336*S4EMHFY04[$8B]+EZ7+Q5<U[R,]
M>%.96Z2_UL>515)J4R*FUL6>UWVE3T)Q)<*;FYNNW1'B$H@ !Q,@
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M&-PEA.EL4:2R93USD\*54V-X-ZNTV0 K;6FT[EW5K%8U  "+(
M                       !'>FK"GQ]AQ:ZDCUKA;T61N2;7Q^4WVIV+UDB
M GCO..T6@4F!O6E["GR:Q,]]-'JVZMSE@R38Q<_"9W*NS@J&BGH*7B]8M" ;
M+H\PS)BK$U/0HCDIF_.U+T\F--_>NQ$[36BS^B#"GR:PRV2ICU;C6Y2SYIM8
MGDL[D7;Q533R<W:IN/,D0W>GACIX(X8&-9%&U&,:U,D:B)DB(<P"B3
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M<.1HR;QI*1-C7\6=2\-W5QAN2-\4CHY6N8]JY.:Y,E1>I4+;%EKDC=4XG;B
M#8R   >:MFY./51?"=ZD/0YR-:KG+L0P\TBRR*Y>G=P)5C:%IU#@ #:U
M       &X87N'.*;F\B_.Q)LSZ6_^#3SOH:E]'51SQ^,U=W6G2A&U=PA>G5&
MDB@ZJ6=E33LFB7-CTS0[3G<( ##  ?6M5SD:U%5RKDB)O4#X;=@_!L]W5E56
MZT%!O3H=+V=2<3-8-P-JZE;>V9KXS*9>CB_W>GJ)%1$1$1$1$38B(<>;DZ^F
MCJQ8-^MG314L%%3,IZ2)L4+$R:UJ;$.X X'6
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M%!7UU/5T;G<I"D:.18W+XR;>A=_;VG%S+8LD=59]89ANH *Y(
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MF_TU\.W%ABOK;R  Y6\
M    #XYK79:S47)<TS3<O6?0                                !T5-
M%2U2955-!,G5)&COS,9+A/#TJYR6*U.7K6DCS_(S0,Q:8\2,"W!N&FKFE@M7
M?2L7V'MIK%::546FM=!"J=,=.QOY(9$&9O:?,@U$:F341$ZD !$
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MQ,BA8V.-B(UK&IDC43<B(<BDRYK9)]?!CQQ3P  TM@
M
M
M                        (CTHZ+67+EKKAN)L=;M=-2IL;-UJWJ=PW+V[
MX%EC?#*^.5CF2,56N:Y,E:J;T5"ZQ'VDO1Q2XHB?6V_4IKPU-C]S9LNA_'J=
MZ>%AQN9T_1D\,3"LX/5<Z"JM==-1W"!\%3$[5?&],E3_ ,<3REK$[]81  9
M        Y,8Z1[61M5SW+DC43-57J0[J"CJ+A614M%"^>HE=JLC8F:N4L5HQ
MT:T^&F1W"ZHRHO"IFG2RGX-ZW?Q>CCHSYZX8W/DB-L)HNT6-I.1NV)XD?4;'
MPT;MJ1]3G]:\.CIV[IB *3+EMEMU63  :P
M
M
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M*#"%'K-U:BYR-RFJ53;_ *6]3?SZ>&X %->\WGJMY2  1
M
M
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M(>6QVBAL=MBH;9 V"FC38U-ZKTJJ]*KUGO *F9F9W*0 #
M
M
M                                             NU-IHDNBW#LF)TN
MZP*D?C+1)_@K)GXV75_#N_( G2]J?;.AO;41J(C41$38B( "
M
M
0                  /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
